Literature DB >> 26849111

The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease.

Jae Whan Keum1, Aram Shin1, Tammy Gillis1, Jayalakshmi Srinidhi Mysore1, Kawther Abu Elneel1, Diane Lucente1, Tiffany Hadzi2, Peter Holmans3, Lesley Jones3, Michael Orth4, Seung Kwak5, Marcy E MacDonald6, James F Gusella7, Jong-Min Lee8.   

Abstract

Huntington disease (HD) is caused by an expanded HTT CAG repeat that leads in a length-dependent, completely dominant manner to onset of a characteristic movement disorder. HD also displays early mortality, so we tested whether the expanded CAG repeat exerts a dominant influence on age at death and on the duration of clinical disease. We found that, as with clinical onset, HD age at death is determined by expanded CAG-repeat length and has no contribution from the normal CAG allele. Surprisingly, disease duration is independent of the mutation's length. It is also unaffected by a strong genetic modifier of HD motor onset. These findings suggest two parsimonious alternatives. (1) HD pathogenesis is driven by mutant huntingtin, but before or near motor onset, sufficient CAG-driven damage occurs to permit CAG-independent processes and then lead to eventual death. In this scenario, some pathological changes and their clinical correlates could still worsen in a CAG-driven manner after disease onset, but these CAG-related progressive changes do not themselves determine duration. Alternatively, (2) HD pathogenesis is driven by mutant huntingtin acting in a CAG-dependent manner with different time courses in multiple cell types, and the cellular targets that lead to motor onset and death are different and independent. In this scenario, processes driven by HTT CAG length lead directly to death but not via the striatal pathology associated with motor manifestations. Each scenario has important ramifications for the design and testing of potential therapeutics, especially those aimed at preventing or delaying characteristic motor manifestations.
Copyright © 2016 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26849111      PMCID: PMC4746370          DOI: 10.1016/j.ajhg.2015.12.018

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  41 in total

Review 1.  No post-genetics era in human disease research.

Authors:  James Gusella; Marcy MacDonald
Journal:  Nat Rev Genet       Date:  2002-01       Impact factor: 53.242

2.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

3.  Huntington's disease mortality in the United States.

Authors:  D J Lanska; L Lavine; M J Lanska; B S Schoenberg
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

4.  Huntington's chorea in children. Report of four cases.

Authors:  R K Byers; J A Dodge
Journal:  Neurology       Date:  1967-06       Impact factor: 9.910

5.  Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression.

Authors:  Ole A Andreassen; Alpaslan Dedeoglu; Violeta Stanojevic; Duncan B Hughes; Susan E Browne; Colin A Leech; Robert J Ferrante; Joel F Habener; M Flint Beal; Melissa K Thomas
Journal:  Neurobiol Dis       Date:  2002-12       Impact factor: 5.996

6.  Onset and rate of striatal atrophy in preclinical Huntington disease.

Authors:  E H Aylward; B F Sparks; K M Field; V Yallapragada; B D Shpritz; A Rosenblatt; J Brandt; L M Gourley; K Liang; H Zhou; R L Margolis; C A Ross
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

7.  Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease.

Authors:  L Djoussé; B Knowlton; M Hayden; E W Almqvist; R Brinkman; C Ross; R Margolis; A Rosenblatt; A Durr; C Dode; P J Morrison; A Novelletto; M Frontali; R J A Trent; E McCusker; E Gómez-Tortosa; D Mayo; R Jones; A Zanko; M Nance; R Abramson; O Suchowersky; J Paulsen; M Harrison; Q Yang; L A Cupples; J F Gusella; M E MacDonald; R H Myers
Journal:  Am J Med Genet A       Date:  2003-06-15       Impact factor: 2.802

8.  Normal caudate glucose metabolism in persons at risk for Huntington's disease.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D Markel; S Berent; J Rothley; A Betley; R Hichwa
Journal:  Arch Neurol       Date:  1987-03

9.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

10.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

View more
  49 in total

1.  2016 William Allan Award: Human Disease Research: Genetic Cycling and Re-cycling.

Authors:  James F Gusella
Journal:  Am J Hum Genet       Date:  2017-03-02       Impact factor: 11.025

2.  Betanin Attenuates Oxidative Stress Induced by 6-OHDA in PC12 Cells via SAPK/JNK and PI3 K Pathways.

Authors:  Elham Hadipour; Masoud Fereidoni; Zahra Tayarani-Najaran
Journal:  Neurochem Res       Date:  2019-12-19       Impact factor: 3.996

3.  Full sequence of mutant huntingtin 3'-untranslated region and modulation of its gene regulatory activity by endogenous microRNA.

Authors:  Kyung-Hee Kim; Kawther Abu Elneel; Jun Wan Shin; Jae Whan Keum; David Seong; Seung Kwak; Ramee Lee; James F Gusella; Marcy E MacDonald; Ihn Sik Seong; Jong-Min Lee
Journal:  J Hum Genet       Date:  2019-07-11       Impact factor: 3.172

4.  Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.

Authors:  Galen E B Wright; Jennifer A Collins; Chris Kay; Cassandra McDonald; Egor Dolzhenko; Qingwen Xia; Kristina Bečanović; Britt I Drögemöller; Alicia Semaka; Charlotte M Nguyen; Brett Trost; Fiona Richards; Emilia K Bijlsma; Ferdinando Squitieri; Colin J D Ross; Stephen W Scherer; Michael A Eberle; Ryan K C Yuen; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2019-05-16       Impact factor: 11.025

5.  Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Authors:  Jussi O T Sipilä; Tommi Kauko; Markku Päivärinta; Kari Majamaa
Journal:  J Neurol       Date:  2017-08-28       Impact factor: 4.849

Review 6.  Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Authors:  Deepa Dash; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 7.  Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: There may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile.

Authors:  David C Rubinsztein; Harry T Orr
Journal:  Bioessays       Date:  2016-08-01       Impact factor: 4.345

8.  Haplotype-based stratification of Huntington's disease.

Authors:  Michael J Chao; Tammy Gillis; Ranjit S Atwal; Jayalakshmi Srinidhi Mysore; Jamshid Arjomand; Denise Harold; Peter Holmans; Lesley Jones; Michael Orth; Richard H Myers; Seung Kwak; Vanessa C Wheeler; Marcy E MacDonald; James F Gusella; Jong-Min Lee
Journal:  Eur J Hum Genet       Date:  2017-08-23       Impact factor: 4.246

9.  N6-Furfuryladenine is protective in Huntington's disease models by signaling huntingtin phosphorylation.

Authors:  Laura E Bowie; Tamara Maiuri; Melanie Alpaugh; Michelle Gabriel; Nicolas Arbez; Danny Galleguillos; Claudia L K Hung; Shreya Patel; Jianrun Xia; Nicholas T Hertz; Christopher A Ross; David W Litchfield; Simonetta Sipione; Ray Truant
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

10.  R-loops promote trinucleotide repeat deletion through DNA base excision repair enzymatic activities.

Authors:  Eduardo E Laverde; Yanhao Lai; Fenfei Leng; Lata Balakrishnan; Catherine H Freudenreich; Yuan Liu
Journal:  J Biol Chem       Date:  2020-08-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.